Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Si's Next-Gen Protein Sequencing ™ Platform in Upcoming Nature Webinar on May 15

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) ('Quantum-Si,' 'QSI' or the 'Company'), The Protein Sequencing Company ™, is pleased to announce an upcoming Nature webinar featuring Gloria Sheynkman, Ph.D., Associate Professor, University of Virginia, who will present new findings from her recent preprint on sequencing proteoform variation with Next-Gen Protein Sequencing ™ (NGPS ™). The live webinar will take place on May 15, 2025, at 8:00 a.m. PDT / 11:00 a.m. EDT.
Proteins are central to cellular function, yet traditional proteomics methods, including mass spectrometry and affinity-based approaches, face challenges in resolving proteoforms, the distinct molecular variation arising from alternative splicing, genetic mutations, and post-translational modifications.
Quantum-Si is pioneering the next generation of protein sequencing technologies, delivering single-amino acid resolution and enabling detection of endogenous proteins with high specificity.
In this context, Dr. Sheynkman's presentation, titled 'Precision Proteomics: Next-Gen Protein Sequencing for Proteoform Detection and Characterization' highlights research from her team's latest study on tropomyosin proteoforms. The work showcases the power of Quantum-Si's Platinum ® family of Next-Gen Protein Sequencing instruments in capturing protein diversity at the single-molecule level.
The webinar is hosted by Nature Portfolio and offers attendees an opportunity to hear directly from Dr. Sheynkman about her lab's innovative multiomic approaches to decoding the proteome.
Webinar Details:
Date:
Time: 8:00 a.m. PDT / 11:00 a.m. EDT
Registration and More Information: Nature Webinar Registration Page
To learn more about the study, read the original press release here:
University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si's Next-Gen Protein Sequencer Platinum
For more information on the webinar, visit: Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company ™, is focused on revolutionizing the growing field of proteomics. The Company's Platinum ® line of instruments enables Next-Gen Protein Sequencing ™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and any financial guidance for the full year 2025. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum ® protein sequencing instruments and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

9 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Forbes

10 hours ago

• Forbes

A Biologist Spotlights 3 ‘Extreme' Snakes — By Strike Speed, Ground Speed And Air Speed

It may not come as a surprise that snakes move quickly, as their prey – often fast-moving animals – ... More demands agility. What many don't realize, however, is just how many snakes are capable of outpacing even humans. In Kung Fu, 'striking like a cobra' symbolizes speed and precision – qualities that are quite real in the snake world. Many snakes feed on creatures like rodents, birds and other small vertebrates, all of which are impressively quick for their size. However, contrary to popular belief, cobras aren't the fastest strikers in the snake world. When it comes to sheer strike speed, few snakes rival the puff adder (Bitis arietans), whose deadly reputation in Africa is well-earned. Responsible for the majority of snakebite fatalities in Africa, the puff adder strikes with both speed and precision. Its strike can reach a blistering 19 feet per second. To put that in perspective, it takes just under 90 milliseconds for the snake's fangs to reach their target, while a typical human blink lasts around 200 milliseconds. In other words, the puff adder can strike faster than the blink of an eye. But while the puff adder is the meanest striker, it isn't the fastest when it comes to locomotion – the process by which an animal physically moves through its environment. Over land and air, there are two snake species that can very well outpace humans. Black Mamba – The Fastest Snake On Land The black mamba is the fastest snake on land, capable of reaching speeds up to 12 miles per hour. When it comes to land speed, few snakes are as fast as the black mamba (Dendroaspis polylepis). Native to sub-Saharan Africa, this long, slender, and remarkably agile species can reach speeds of 9 to 12 miles per hour over short distances, making it the fastest snake in the world on land. Don't be fooled by web searches claiming the sidewinder rattlesnake is the world's fastest snake – a misconception that's been widely perpetuated online. While sidewinding is an efficient way to move across loose desert sand, it's not particularly fast. Biomechanical research shows that sidewinders top out at around 2.2 miles per hour on the ground. By contrast, the black mamba's smooth lateral undulation and powerful muscular coordination allow it to traverse open ground with astonishing speed. Its movement is not only fast but also controlled and deliberate. Black mambas are often seen cruising the savanna with their head and neck held high, using their keen eyesight to scan for danger or track prey – typically small mammals such as hyraxes, bush babies, and rodents. Despite their fearsome reputation, black mambas are not inherently aggressive. In reality, they are shy, secretive snakes that go out of their way to avoid conflict. Like most snakes, they strike only when they feel threatened or cornered. (Sidebar: Long considered the world's second-longest venomous snake at up to 15 feet, the black mamba has recently slipped to fifth place. Curious which four venomous snakes outrank it in length? Read the full story here.) Paradise Flying Snake – The Fastest Snake In Air This gorgeous paradise flying snake has the amazing ability to use its body to control a free fall. ... More By flattening its ribs, it is able to "glide" through the air, making it a very unique species of snake. The paradise flying snake (Chrysopelea paradisi) is not capable of flight in the traditional sense, but it has evolved a remarkable ability to glide through the air, making it one of the most fascinating – and fastest moving – snakes in the world. Found in the rainforests of Southeast Asia, this snake uses its unique body structure to 'fly' from tree to tree by flattening its ribs and undulating through the air. Its gliding ability allows it to cover distances of up to 100 feet in a single leap, often traveling at speeds of up to 25 miles per hour. Measured by sheer velocity, that makes it the fastest snake in the world – though it only reaches these speeds while gliding. The snake's technique involves launching itself from a high point and using the air to support its long, flattened body, making it seem like it's flying. In reality, the snake is engaging in controlled freefall, steering with precise body movements to direct its glide. This specialized form of locomotion helps it escape predators, hunt for prey and move efficiently between trees in its dense forest habitat. There are five species in the genus Chrysopelea, but only four have documented gliding behavior. The exception is the Sri Lankan flying snake (Chrysopelea taprobanica), for which data on aerial locomotion is still lacking. While the other species are all considered skilled aerial travelers, biomechanical research suggests that the paradise flying snake is the fastest glider among them. While the paradise flying snake is venomous, its venom is mild and poses little danger to humans. Its primary diet consists of reptiles, birds and other small vertebrates, and its ability to glide gives it a distinct advantage in ambushing prey or escaping threats in the treetops. Curious to see how your fear of animals stacks up? Take our quick quiz to find out fast-moving creatures — like snakes that strike fast, slither, swim and glide — send a shiver down your spine: Fear Of Animals Scale

Yahoo

12 hours ago

• Yahoo

Meet the tiny Australian Moth that travels 1,000 km and navigates using the stars

An Australian moth follows the stars during its yearly migration, using the night sky as a guiding compass, according to a new study. When temperatures heat up, nocturnal Bogong moths fly about 1,000 kilometres to cool down in caves by the Australian Alps. They later return home to breed and die. Birds routinely navigate by starlight, but the moths are the first known invertebrates, or creatures without a backbone, to find their way across such long distances using the stars. Scientists have long wondered how the moths travel to a place they've never been. A previous study hinted that Earth's magnetic field might help steer them in the right direction, along with some kind of visual landmark as a guide. Related Does cutting off rhinos' horns protect them from poachers? New study supports controversial approach Since stars appear in predictable patterns each night, scientists suspected they might help lead the way. They placed moths in a flight simulator that mimicked the night sky above them and blocked out the Earth's magnetic field, noting where they flew. Then they scrambled the stars and saw how the moths reacted. When the stars were as they should be, the moths flapped in the right direction. But when the stars were in random places, the moths were disoriented. Their brain cells also got excited in response to specific orientations of the night sky. The findings were published Wednesday in the journal Nature. It 'was a very clean, impressive demonstration that the moths really are using a view of the night sky to guide their movements,' said Kenneth Lohmann, who studies animal navigation at the University of North Carolina at Chapel Hill and was not involved with the new research. Researchers don't know what features of the night sky the moths use to find their way. It could be a stripe of light from the Milky Way, a colourful nebula or something else entirely. Whatever it is, the insects seem to rely on that, along with Earth's magnetic field, to make their journey. Related Rare snail that can 'slurp up earthworms like noodles' caught on camera laying an egg from its neck Scientists use special 'squeezing' and electrical probes to collect sperm from endangered kākāpō Other animals harness the stars as a guide. Birds take celestial cues as they soar through the skies, and dung beetles roll their remains short distances while using the Milky Way to stay on course. It's an impressive feat for Bogong moths, whose brains are smaller than a grain of rice, to rely on the night sky for their odyssey, said study author David Dreyer with Lund University in Sweden. 'It's remarkable that an animal with such a tiny brain can actually do this,' Dreyer said.